摘要: Lung cancer is the commonest cause of cancer-related mortality worldwide. Surgery mainstay curative therapy for early stage non-small cell lung (NSCLC) with or without adjuvant chemotherapy to reduce risk relapse. For inoperable locally advanced NSCLC, and small (SCLC) limited thorax, chemoradiotherapy given intent. However, majority patients have disseminated, metastatic disease at presentation palliative aims improving symptoms, optimising quality life extending survival may be appropriate.
manchester.ac.uk
springer.com
core.ac.uk参考文章(41)
Assessing EGFR mutations. The New England Journal of Medicine. ,vol. 354, pp. 526- ,(2006) , 10.1056/NEJMC052564
Jeyanthi Ramanarayanan, Ganapathy S Krishnan, Review: hepatotoxicity and EGFR inhibition. Clinical advances in hematology & oncology. ,vol. 6, pp. 200- 201 ,(2008)
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736
William D Travis, Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee. Histopathology. ,vol. 54, pp. 3- 11 ,(2009) , 10.1111/J.1365-2559.2008.03179.X
Rafael Rosell, Miquel Taron, Jose Javier Sanchez, Luis Paz-Ares, None, Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. Future Oncology. ,vol. 3, pp. 277- 283 ,(2007) , 10.2217/14796694.3.3.277
William Pao, Vincent A Miller, Katerina A Politi, Gregory J Riely, Romel Somwar, Maureen F Zakowski, Mark G Kris, Harold Varmus, Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain PLoS Medicine. ,vol. 2, pp. e73- ,(2005) , 10.1371/JOURNAL.PMED.0020073
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos, EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib The New England Journal of Medicine. ,vol. 352, pp. 786- 792 ,(2005) , 10.1056/NEJMOA044238
Raffaele Califano, Fiona H. Blackhall, Giovanna Finocchiaro, Luca Toschi, Nicholas Thatcher, Federico Cappuzzo, Lucio Crinò, EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data? Targeted Oncology. ,vol. 3, pp. 173- 186 ,(2008) , 10.1007/S11523-008-0084-7
Romano Danesi, Giuseppe Pasqualetti, Elisa Giovannetti, Francesco Crea, Giuseppe Altavilla, Mario Del Tacca, Rafael Rosell, Pharmacogenomics in non-small-cell lung cancer chemotherapy Advanced Drug Delivery Reviews. ,vol. 61, pp. 408- 417 ,(2009) , 10.1016/J.ADDR.2009.03.001
Sarit Aviel-Ronen, Fiona H. Blackhall, Frances A. Shepherd, Ming-Sound Tsao, K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review Clinical Lung Cancer. ,vol. 8, pp. 30- 38 ,(2006) , 10.3816/CLC.2006.N.030